BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...
BriaCell (NASDAQ: BCTX, BCTXW) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has ...
H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...
The stock markets in the US opened higher on February 4 as investors remained cautious about China’s stance on the Trump tariffs. Salesforce shares were trading 1.64% higher in the early market ...
Palantir reported fourth-quarter revenue of $827.52 million, beating the consensus estimate of $775.91 million. The company reported fourth-quarter adjusted earnings of 14 cents per share, beating ...